Literature DB >> 386761

Role of vasoconstrictor mechanisms in the control of left ventricular performance of the normal and damaged heart.

J N Cohn, I Mashiro, T B Levine, J Mehta.   

Abstract

The effect on the left ventricle of changes in the state of the arterial vasculature is best identified by utilizing calculations of pulsatile rather than steady flow phenomena. Impedance is the most satisfactory term to describe this effect. The normal ventricle compensates for changes in impedance largely by changes in preload, but the damaged heart loses this compensatory ability and its stroke volume becomes inversely related to outflow resistance. Patients with heart failure behave in a similar fashion and pharmacologic vasodilation may induce marked improvement in left ventricular pump function. Inappropriate vasoconstriction in heart failure may result from stimulation of the sympathetic or renin-angiotensin system. Early experience with converting enzyme inhibitors suggests that blockade of the formation of angiotensin II may be a useful means of treating some patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 386761     DOI: 10.1016/0002-9149(79)90238-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  The vasopressor system in patients with heart failure due to idiopathic dilated cardiomyopathy--influence of the clinical stage of disease and of chronic drug treatment.

Authors:  V Mitrovic; J Thormann; P Kornecki; M Volz; H Neuss; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study.

Authors:  B Herrlin; O Nyquist; C Sylvén
Journal:  Br Heart J       Date:  1991-09

3.  Hyponatraemia as a marker for high renin heart failure.

Authors:  T B Levine; J A Franciosa; T Vrobel; J N Cohn
Journal:  Br Heart J       Date:  1982-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.